
VAS-101 (Vasceptor) Receives Orphan Drug Designation for Sickle Cell Disease
On 12 June 2025, Vascarta Inc. announced its receipt of the Orphan Drug Designation from the US Food and Drug Administration (FDA) for its lead drug candidate, VAS-101 (Vasceptor), to treat sickle cell disease (SCD). This designation will provide VAS-101 …